Health Care Winners & Losers: Alkermes
Updated from 3:40 p.m. ET
A J.P. Morgan analyst said Tuesday that health care is currently the most attractive sector in the market, and stocks in health care could make an average gain of 25% in 2009.
Thomas J. Lee upgraded the health care sector to Overweight from Neutral, saying the stocks are generally inexpensive compared with their expected earnings, and profit growth could exceed Wall Street expectations. Lee said pharmacy benefits managers, biotechnology companies and pharmaceutical companies are the most attractive areas of the industry.
Health care stocks are getting stronger but are not yet at their peak value, as consumer staple companies are, Lee wrote. He said shares of health care service companies are closer to a peak.
"Given the continued weak (economic) outlook, coupled with low visibility, health care is likely to continue outperforming," he said. The analyst also believes that health care is less vulnerable to economic weakness than many other industries.
Lee said there could be significant buyout activity in the sector in keeping with shareholder demand, and big drug companies may look to combine or buy smaller companies to fight off the revenue they will lose as patents on key products expire. In just such a move, Eli Lilly (LLY) bought cancer drug maker ImClone Systems for more than $6 billion in November, and some analysts are expecting similar deals to follow. Lee said biotechnology stocks may make the largest gains, along with health care equipment and life science tools and services. He expects little stock movement from facility operators and suppliers.Select the service that is right for you!
COMPARE ALL SERVICESAction Alerts PLUS
TRY IT FREEJim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
Product Features:
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
TheStreet Quant Ratings
TRY IT FREENew! $49.95/yr
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
Product Features:
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Stocks Under $10
TRY IT FREEDavid Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.
Product Features:
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts
- Weekly roundups
Dividend Stock Advisor
TRY IT FREEJim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
Product Features:
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
TRY IT FREEAll of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
Product Features:
- Real Money + Doug Kass + 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Options Profits
TRY IT FREEOur options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
Product Features:
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV